What happens when you start Mounjaro in the UK

Step 1, the first injection and the days that follow

The first thing that happens after your prescriber approves treatment is straightforward: your pen arrives the next working day, and you give yourself the initial 2.5 mg dose, typically in the abdomen, thigh or upper arm. The 2.5 mg starting dose exists primarily to let your digestive system adjust, not to produce rapid weight loss. Think of it as your body learning what tirzepatide does rather than doing it at full effect.

For many people, nausea is the dominant experience in the first few days, sometimes accompanied by reduced appetite, mild indigestion or loose stools. These effects tend to be most noticeable in the 24 to 48 hours after injection and ease as the week progresses. Keeping the pen in the fridge door alongside everyday items serves as a useful routine anchor: same day, same time, same place each week helps the rhythm stick. The NHS patient information for tirzepatide sets out the common side effects in detail and is worth reading before your first dose.

A small number of people notice very little in the first week at all. That is not a sign it is not working; the mechanism builds as the drug reaches steady state in your system.

Step 2, appetite changes and the weeks of titration

Between roughly weeks four and twelve, if your prescriber increases the dose, the appetite-reducing effect tends to become more pronounced. GIP and GLP-1 receptors work together to slow gastric emptying and signal fullness to the brain, you may find that meals that previously felt unremarkable now feel complete much sooner, or that the background noise of hunger is simply quieter than before.

This is also the stage where some people notice unexpected effects that are less discussed. Subtle changes like dry or chapped skin around the lips can occur, possibly linked to reduced food and fluid intake, there is a detailed look at this specific side effect if it concerns you. Gastrointestinal symptoms often settle during this window as the dose stabilises, though they may briefly return after each increase. Your prescriber reviews your progress before any step up; at nume, that review happens before every repeat order, not just at the start.

Protein intake, hydration and keeping active all support what the medicine is doing, personal plans sit with your prescriber or a dietitian, but the general principle holds across the clinical evidence.

Step 3, what the evidence shows over months of treatment

The SURMOUNT-1 trial, published in the New England Journal of Medicine, followed thousands of adults over 72 weeks. At the 15 mg maintenance dose, participants lost around 20 to 21% of body weight on average, figures that placed tirzepatide among the most effective licensed weight-management medicines available. A more recent head-to-head comparison with semaglutide 2.4 mg (SURMOUNT-5, 2025) found tirzepatide produced greater average weight reduction over the same period.

These numbers describe population averages from controlled trials, not guarantees for any individual. How much weight any person loses depends on the dose reached, adherence to the once-weekly schedule, and the dietary and activity changes made alongside treatment. NICE recommends reviewing continuation if less than 5% weight loss is achieved after six months at the highest tolerated dose, per NICE technology appraisal TA1026.

Weight loss is typically gradual and non-linear. A plateau at a particular dose is common before a titration step; it is not a sign that treatment has stopped working. For people who are curious about how treatment is accessed privately versus through the NHS, the context around Mounjaro costs in the UK is worth reading separately.

Step 4, ongoing treatment, monitoring and what to watch for

After reaching a maintenance dose, what happens on Mounjaro shifts from adjustment to consolidation. Most people find the GI side effects have largely settled. The job becomes sustaining the habits that support the medicine: eating enough protein, staying hydrated, and keeping active in whatever form fits your life.

A few things warrant prompt attention regardless of where you are in treatment. Severe, persistent stomach pain that radiates toward the back (particularly with vomiting) should lead straight to medical help, because acute pancreatitis, while uncommon, is a recognised risk with GLP-1 medicines that the MHRA flagged formally in early 2026. Signs of a serious allergic reaction, significant dehydration from ongoing vomiting or diarrhoea, and gallbladder symptoms all require the same response: contact a doctor or call 111, not a review of your app. Suspected side effects can be reported through the MHRA Yellow Card scheme.

Questions that sit outside the expected pattern (such as what happens if you have a pre-existing condition like multiple sclerosis) deserve a direct conversation with a prescriber rather than a general answer. Our clinical team is available to discuss your specific situation through a free consultation with our prescribers, reviewed the same day your answers arrive.